Intramural Research Program
National Institutes of Health
Baltimore, Maryland 21224.
Charles R. Schuster
Intramural Research Program
National Institutes of Health
Baltimore, Maryland 21224.
1. Arndt IO, Dorozynsky L, Woody GE, McLellan AT, O'Brien CP. Desipramine treatment of cocaine dependence in methadone-maintained patients. Arch Gen Psychiatry 1992;49:888-893.
2. Benowitz NL. How toxic is cocaine? In: Cocaine: scientific and social dimensions. Chichester: John Wiley & Sons, Ciba Foundation Symposium 166, 1992;125-148.
3. Butynski W, Reda JL, Canova D, et al. State resources and services related to alcohol and drug abuse profile data. Washington, DC: National Association of State Alcohol and Drug Abuse Directors, 1991.
4. Caine SG, Koob GF. Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science 1993;260:1814-1816.
5. Carroll FI, Lewin AH, Boja JW, Kuhar MJ. Cocaine receptor: biochemical characterization and structure-activity relationships of cocaine analogues at the dopamine transporter. J Med Chem 1992;35:969-981.
6. Carroll ME, Lac ST, Acensio M, Kragh R. Fluoxetine reduces intravenous cocaine self-administration in rats. Pharmacol Biochem Behav 1990;35:237-244.
7. Chilcoat HD, Schutz CG. Racial/ethnic differences in crack use within neighborhoods. Addiction Res 1994; in press.
8. Chow JM, Menchen SL, Paul BD, Stein RJ. Vascular changes in the nasal submucosa of chronic cocaine addicts. Am J Forensic Med Pathol 1990;11:136-143.
9. Cunningham KA, Callahan PM. Monoamine reuptake inhibitors enhance the discriminative state induced by cocaine in the rat. Psychopharmacology 1991;104:177-180.
10. Cunningham KA, Paris JM, Goeders NE. Serotonin neurotransmission in cocaine sensitization. In: Kalivas PW, Samson HH, eds. The neurobiology of drug and alcohol addiction. New York: The New York Academy of Sciences, 1992;117-127.
11. Dackis CA, Gold MS. Pharmacological approaches to cocaine addiction. J Subst Abuse Treat 1985;2:139-145.
12. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988;85:5274-5278.
13. Dworkin SI, Smith JE. Neurobehavioral pharmacology of cocaine. In: Clouet D, Asghar K, Brown R, eds. Mechanisms of cocaine abuse and toxicity. Washington, DC: U.S. Government Printing Office, 1988;185-198.
14. Dwoskin LP, Peris J, Yasuda RP, Philpott K, Zahniser NR. Repeated cocaine administration results in supersensitivity of striatal D-2 autoreceptors to pergolide. Life Sci 1988;42:255-262.
15. Evans SM, Cone EJ, Marco AP, Henningfield JE. A comparison of the arterial kinetics of smoked and intravenous cocaine. In: Harris L, eds. Problems of drug dependence, 1992. Rockville, MD: U.S. Department of Health and Human Services, 1993;343.
16. Fischman MW, Foltin RW. The effects of desipramine maintenance on cocaine self-administration in humans. Psychopharmacology 1988;96:S20.
17. Foltin RW, Fischman MW. Ethanol and cocaine interactions in humans: cardiovascular consequences. Pharmacol Biochem Behav 1989;31:877-883.
18. Foltin RW, Fischman MW. Smoked and intravenous cocaine in humans: acute tolerance, cardiovascular and subjective effects. J Pharmacol Exp Ther 1991;257:247-261.
19. Gastfriend D, Mendelson J, Mello N, Teoh S, Reif S. Buprenorphine pharmacotherapy for concurrent heroin and cocaine dependence. Am J Addict 1993;2:269-278.
20. Gawin F, Allen D, Hurnblestone B. Outpatient treatment of "crack" cocaine smoking with flupenthixol decanoate. Arch Gen Psychiatry 1989;46:322-325.
21. Gawin FH, Kleber HD. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations. Arch Gen Psychiatry 1986;43:107-113.
22. Gawin FH, Kleber HD, Byck R, et al. Desipramine facilitation of initial cocaine abstinence. Arch Gen Psychiatry 1989;46:117-121.
23. Goeders NE, Smith JE. Intracranial cocaine self-administration into the medial prefrontal cortex increases dopamine turnover in the nucleus accumbens. J Pharmacol Exp Ther 1993;265:592-600.
24. Grilli M, Wright AG, Hanbauer I. Characterization of [3H]dopamine uptake sites and [3H]cocaine recognition sites in primary cultures of mesencephalic neurons during in vitro development. J Neurochem 1991;56:2108-2115.
25. Hearn WL, Flynn DD, Hime GW, et al. Cocaethylene: a unique cocaine metabolite displays high affinity for the dopamine transporter. J Neurochem 1991;56:698-701.
26. Hearn WL, Rose S, Wagner J, Ciarleglios A, Mash DC. Cocaethylene is more potent that cocaine in mediating lethality. Pharmacol Biochem Behav 1991;3:531-533.
27. Henry DJ, White FJ. Electrophysiological correlates of psychomotor stimulant-induced sensitization. In: Kalivas PW, Samson HH, eds. The neurobiology of drug and alcohol addiction. New York: The New York Academy of Sciences, 1992;654:88-100.
28. Hime GW, Hearn WL, Rose S, Cofino J. Analysis of cocaine and cocaethylene in blood and tissues by GD-NPD and GC-ion trap mass spectrometry. J Anal Toxicol 1991;15:241-245.
29. Hubner CB, Moreton JE. Effects of selective D1 and D2 dopamine antagonists on cocaine self-administration in the rat. Psychopharmacology 1991;105:151-156.
30. Hurd YL, Weiss F, Anden N-E, Koob GF, Ungerstedt U. Cocaine reinforcement and extracellular dopamine overflow in rat nucleus accumbens: an in vivo microdialysis study. Brain Res 1989;498:199-203.
31. Izenwasser S, Cox BM. Daily cocaine treatment produces a persistent reduction of [3H]dopamine uptake in vitro in rat nucleus accumbens but not in striatum. Brain Res 1990;531:338-341.
32. Jacobs IG, Roszler MH, Kelly JK, Klein MA, Kling GA. Cocaine abuse: neurovascular complications. Radiology 1989;170:223-227.
33. Johanson CE, Barrett JE. The discriminative stimulus effects of cocaine in pigeons. J Pharmacol Exp Ther 1993;267:1-8.
34. Johanson CE, Fischman MF. The pharmacology of cocaine related to its abuse. Pharmacol Rev 1989;41:3-52.
35. Johanson CE, Schuster CR. Animal models of drug self-administration. In: Mello NK, ed. Advances in substance abuse: behavioral and biological research. Greenwich, CT, JAI Press, 1981; 219-297.
36. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992;267:2750-2755.
37. Kalivas PW, Duffy P. Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals. J Neurosci 1993;13:266-275.
38. Kalivas PW, Duffy P. Time course of extracellular dopamine and behavioral sensitization to cocaine. II. Dopamine perikarya. J Neurosci 1993;13:276-284.
39. Kalivas PW, Sorg BA, Hooks MS. The pharmacology and neural circuitry of sensitization to psychostimulants. Behav Pharmacol 1993;4:315-334.
40. Kalivas PW, Striplin CD, Steketee JD, Klitenick MA, Duffy P. Cellular mechanisms of behavioral sensitization to drugs of abuse. In: Kalivas PW, Samson HH, eds. The neurobiology of drug and alcohol addiction. New York: The New York Academy of Sciences, 1992;654:128-135.
41. Kandel DB, Faust R. Sequences and stages in patterns of adolescent drug use. Arch Gen Psychiatry 1975;32:923-932.
42. Kandel DB, Yamaguchi K. From beer to crack: developmental patterns of involvement in drugs. Am J Public Health 1993;83:851-855.
43. Kilbey MM, Breslau N, Andreski P. Cocaine use and dependence in young adults: associated psychiatric disorders and personality traits. Drug Alcohol Depend 1992;29:283-290.
44. Kilty JE, Lorang D, Amara SG. Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science 1991;254:578-579.
45. Kitayama S, Shimada S, Xu H, Markham L, Donovan DM, Uhl GR. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Natl Acad Sci USA 1992;89:7782-7785.
46. Kleven MS, Anthony EW, Woolverton WL. Pharmacological characterization of the discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 1990;254:312-317.
47. Kleven MS, Woolverton WL, Seiden LS. Lack of long-term monoamine depletions following continuous or repeated exposure to cocaine. Brain Res Bull 1988;21:233-237.
48. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science 1988;242:715-723.
49. Koob GF, Le HT, Creese I. The D1 dopamine receptor antagonist SCH 23390 increases cocaine self-administration in the rat. Neurosci Lett 1987;79:315-320.
50. Kosten RT, Morgan CM, Falcione J, Schottenfeld RS. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch Gen Psychiatry 1992;49:894-898.
51. Kuhar MJ, Ritz MC, Boja JW. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 1991;14:299-302.
52. Levin FR, Lehman AF. Meta-analysis of desipramine as an adjunct in the treatment of cocaine addiction. J Clin Psychopharmacol 1991;11:374-378.
53. Lillie-Blanton M, Anthony JC, Schuster CR. Probing the meaning of racial/ethnic group comparisons in crack-cocaine smoking. JAMA 1993;269:993-997.
54. Lindenbaum GA, Carroll SF, Daskal I, Kapusnick R. Patterns of alcohol and drug abuse in an urban trauma center: the increasing role of cocaine abuse. J Trauma 1989;29:1654-1658.
55. Loh EA, Roberts DCS. Break-points on a progressive ratio schedule reinforced by intravenous cocaine increase following depletion of forebrain serotonin. Psychopharmacology 1990;101:262-266.
56. Lutiger B, Graham K, Einarson TR, Koren G. Relationship between gestational cocaine use and pregnancy outcome: a meta-analysis. Teratology 1991;44:405-414.
57. Maldonado R, Robledo P, Chover AJ, Caine SB, Koob GF. D1 dopamine receptors in the nucleus accumbens modulate cocaine self-administration in the rat. Pharmacol Biochem Behav 1993;45:239-242.
58. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult outcome of hyperactive boys. Arch Gen Psychiatry 1993;50:565-576.
59. Markou A, Koob GF. Postcocaine anhedonia: an animal model of cocaine withdrawal. Neuropsychopharmacology 1991;4:17-26.
60. Mello NK, Mendelson JH, Bree MP, Lukas SE. Buprenorphine suppresses cocaine self-administration by rhesus monkeys. Science 1989;245:859-862.
61. Mendelson JH, Mello NK, Teoh SK, Elingboe J, Cochin J. Cocaine effects on pulsatile secretion of anterior pituitary, gonadal, and adrenal hormones. J Clin Endocrinol Metab 1989;69:1256-1260.
62. Ng JP, Hubert GW, Justice JB. Increased stimulated release and uptake of dopamine in nucleus accumbens after repeated cocaine administration as measured by in vivo voltammetry. J Neurochem 1991;56:1485-1492.
63. National Institute on Drug Abuse. National survey results on drug use from The Monitoring the Future Study, 1975-1992. Government Publication Number 93-3597, 1993.
64. O'Brien CP, Childress AR, Arndt IO, McLellan AT, Woody GE, Maany I. Pharmacological and behavioral treatments of cocaine dependence: controlled studies. J Clin Psychiatry 1988;49(Suppl):17-22.
65. Ostrea EM, Brady M, Gause S, Raymundo AL, Stevens M. Drug screening of newborns by meconium analysis: a large-scale, prospective, epidemiologic study. Pediatrics 1992;89:107-113.
66. Parsons LH, Smith AD, Justice JB. Basal extracellular dopamine is decreased in the rat nucleus accumbens during abstinence from chronic cocaine. Synapse 1991;9:60-65.
67. Perez-Reyes M, Jeffcoat AR. Ethanol/cocaine interaction: cocaine and cocaethylene plasma concentrations and their relationship to subjective and cardiovascular effects. Life Sci 1992;51:553-563.
68. Pettit H, Justice J Jr. Dopamine in the nucleus accumbens during cocaine self-administration as studied by in vivo microdialysis. Pharmacol Biochem Behav 1989;34:899-904.
69. Pettit HO, Justice JB. Effect of dose on cocaine self-administration behavior and dopamine levels in the nucleus accumbens. Brain Res 1991;539:94-102.
70. Pettit HO, Pan H-T, Parsons LH, Justice JB. Extracellular concentrations of cocaine and dopamine are enhanced during chronic cocaine administration. J Neurochem 1990;55:798-804.
71. Post RM, Lickfeld A, Squillace KM, Contel NR. Drug-environment interaction: context dependency of cocaine induced behavioral sensitization. Life Sci 1981;28:755-760.
72. Pulvirenti L, Maldonado-Lopez R, Koob GF. MNDA receptors in the nucleus accumbens modulate intravenous cocaine but not heroin self-administration in the rat. Brain Res 1992;594:327-330.
73. Racine A, Joyce T, Anderson R. The association between prenatal care and birth weight among women exposed to cocaine in New York City. JAMA 1993;270:13.
74. Reith MEA, de Costa B, Rice KC, Jacobson AE. Evidence for mutually exclusive binding of cocaine, BTCP, GBR 12935, and dopamine to the dopamine transporter. Eur J Pharmacol 1992;227:417-425.
75. Ritz MC, Cone EJ, Kuhar MJ. Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: a structure-activity study. Life Sci 1990;46:635-645.
76. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987;237:1219-1223.
77. Roberts DCS, Loh EA, Vickers G. Self-administration of cocaine on a progressive ratio schedule in rats: dose-response relationship and effect of haloperidol pretreatment. Psychopharmacology 1989;97:535-538.
78. Robinson TE. Stimulant drugs and stress: factors influencing individual differences in the susceptibility to sensitization. In: Kalivas PW, Barnes CD, eds. Sensitization in the nervous systems. Caldwell, NJ: Telford Press, 1988;145-173.
79. Rossetti ZL, Hmaidan Y, Gessa GL. Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur J Pharmacol 1992;221:227-234.
80. Rounsaville BJ, Foley-Anton S, Carroll K, Budde D, Pursoff BA, Gawin F. Psychiatric diagnosis of treatment-seeking cocaine abusers. Arch Gen Psychiatry 1991;48:43-51.
81. Rubin RB, Neugarten J. Cocaine rhabdomyolysis masquerading as myocardial ischemis. Am J Med 1989;86:551-553.
82. Satel SL, Price LH, Palumbo JM, et al. Clinical phenomenology and neurobiology of cocaine abstinence: a prospective inpatient study. Am J Psychiatry 1991;148:1712-1716.
83. Schenk S, Valadez A, McNamara C, et al. Development and expression of sensitization to cocaine's reinforcing properties: role of NMDA receptors. Psychopharmacology 1993;111:332-338.
84. Schuster CR, Gust S. Cocaine: challenges to research. In: Edwards G, Strang J, Jaffe JH, eds. Drugs, alcohol, and tobacco. Oxford: Oxford University Press, 1993;146-155.
85. Seiden LS, Ricaurte GA. Neurotoxicity of methamphetamine and related drugs. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987;359-366.
86. Shimada S, Kitayama S, Lin C-L, et al. Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science 1991;254:576-577.
87. Spealman RD, Bergman J, Madras BK, Melia KF. Discriminative stimulus effects of cocaine in squirrel monkeys: involvement of dopamine receptor subtypes. J Pharmacol Exp Ther 1991;258:945-953.
88. Stewart J, Vezina P. Microinjections of SCH-23390 into the ventral tegmental area and substantia nigra pars reticulata attenuate the development of sensitization to the locomotor activating effects of systemic amphetamine. Brain Res 1989;495:401-406.
89. Volkow ND, Fowler JS, Wolf AP, et al. Changes in brain glucose metabolism in cocaine dependence and withdrawal. Am J Psychiatry 1991;148:621-626.
90. Volkow ND, Mullani N, Gould KL, Adler S, Krajewski K. Cerebral blood flow in chronic cocaine users: a study with positron emission tomography. Br J Psychiatry 1988;152:641-648.
91. Weddington WW, Brown BS, Haertzen CA, et al. Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Am J Drug Alcohol Abuse 1991;17:137-152.
92. Weed MR, Vanover KE, Woolverton WL. Reinforcing effect of the D1 dopamine agonist SKF 81297 in rhesus monkeys. Psychopharmacology 1993;113:51-52.
93. Weiss F, Markou A, Lorang MT, Koob GF. Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Res 1992;593:314-318.
94. Weiss F, Paulus MP, Lorang MR, Koob GF. Increases in extracellular dopamine in the nucleus accumbens by cocaine are inversely related to basal levels: effects of acute and repeated administration. J Neurosci 1992;12:4372-4380.
95. Winger G, Skjoldager P, Woods JH. Effects of buprenorphine and other opioid agonists and antagonists on aflentanil- and cocaine-reinforced responding in rhesus monkeys. J Pharmacol Exp Ther 1992;261:311-317.
96. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev 1987;94:469-492.
97. Witkin JM, Nichols DE, Terry P, Katz JL. Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injection. J Pharmacol Exp Ther 1991;257:706-713.
98. Woody GE, McLellan AT, Luborsky L, O'Brien CP. Sociopathy and psychotherapy outcome. Arch Gen Psychiatr 1985;42:1081-1086.
99. Woolverton WL. Effects of a D1 and a D2 dopamine antagonist on the self-administration of cocaine and piribedil by rhesus monkeys. Pharmacol Biochem Behav 1986;24:531-535.
100. Woolverton WL, Virus RM. The effects of a D1 and a D2 dopamine antagonist on behavior maintained by cocaine or food. Pharmacol Biochem Behav 1989;32:691-697.
101. Yi S-J, Johnson KM. Effects of acute and chronic administration of cocaine on striatal uptake, compartmentalization and release of [3H]dopamine. Neuropharmacology 1990;29:475-486.
1 References for the major national surveys including DAWN can be obtained from the authors or directly from the National Institute on Drug Abuse, the Substance Abuse Mental Health Services Administration, or the National Institute of Justice.
2 Eighth- and tenth-grade students were studied in the most recent surveys. However, there are not sufficient data to discuss trends in prevalence rates in these age groups.
3 References included in ref. 34 are not repeated in the present chapter.
4 See ref. 34 for references to earlier studies.